Developer docs
API playgroundTry for free, no card

Search company profiles

Nucleus Network

Full company profile

uuid0009o48

Namestring
Nucleus Network
Legal namestring
Nucleus Network
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Nucleus Network is an Australian Contract Research Organization (CRO) founded in 2004 and headquartered in Melbourne, specializing in the conduct of early-phase clinical trials. The company serves pharmaceutical and biotechnology companies as its primary customer segment, with secondary engagement of academic and institutional research organizations. Its core offering centers on Phase I and early-phase clinical research execution, with particular domain expertise in vaccines, therapeutics, and tropical disease research including tuberculosis, dengue, and malaria. Nucleus Network operates within Australia's Clinical Trial Notification Scheme, which enables 4-8 week regulatory approval timelines, providing a structural speed advantage for sponsor drug development programs.

The company generates revenue through professional services fees for clinical trial execution on a per-study basis, with pricing negotiated quote-by-quote rather than published. As a wholly-owned portfolio company of Blackstone, Nucleus Network has pursued growth through M&A, including the 2019 acquisition of Prism Clinical Research and the August 2025 acquisition of UK-based Hammersmith Medicines Research Ltd, which extended operations beyond Australia into the United Kingdom. The company engages in event-driven go-to-market activity, notably through participation in industry conferences such as BioAsia 2026 in Hyderabad, where it positioned itself alongside the Queensland Government delegation as a strategic partner for India-Australia biotech collaboration. As of early 2026, Blackstone is evaluating a potential sale of Nucleus Network as part of its portfolio diversification strategy.

Short descriptiontext

Nucleus Network is an Australian CRO specializing in early-phase clinical trials for pharmaceutical and biotechnology companies. The company leverages Australia's fast-track Clinical Trial Notification Scheme and has expanded into the UK via the Hammersmith Medicines Research acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
early phase clinical trials, contract research organization, phase I trials, vaccine clinical research, tropical disease trials
Industry1 code
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
NAICS code2 codes
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) / Early-Phase Clinical Trial Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Nucleus Network operates as a Contract Research Organization (CRO), providing clinical trial services to pharmaceutical and biotechnology companies. Revenue is generated through service fees for conducting clinical research trials.

simplywall.st
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nucleus Network operates as a Contract Research Organization (CRO) conducting Phase I and early-phase clinical trials for pharmaceutical and biotechnology companies. Services are delivered from Australia-based facilities with access to the Clinical Trial Notification Scheme, enabling 4-8 week trial approval timelines. The company specializes in vaccine and therapeutics clinical research, including tropical disease studies for tuberculosis, dengue, and malaria.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Nucleus Network is a Contract Research Organization (CRO) specializing in early-phase clinical trials. Based in Australia, the company conducts Phase I and early-phase clinical research for pharmaceutical and biotechnology companies. The company is noted for fast clinical trial approval pathways and expertise in tropical health research, vaccines, and therapeutics for diseases such as tuberculosis, dengue, and malaria. Nucleus Network serves as a strategic partner for biotech collaboration between Australia and international markets.

Product and service3 records
1Early-Phase Clinical Trial Services
CategoryContract Research Organization Services
Description

Contract Research Organization (CRO) services delivering Phase I and early-phase clinical trials for pharmaceutical and biotechnology sponsors, leveraging Australia's Clinical Trial Notification Scheme for accelerated 4-8 week approvals.

2Vaccines and Therapeutics Clinical Research
CategoryVaccines and Therapeutics Clinical Research
Description

Clinical research services focused on vaccine and therapeutics development programs for pharmaceutical and biotechnology sponsors.

3Tropical Disease Clinical Research
CategoryTropical Disease Clinical Research
Description

Specialized clinical research services for tropical disease drug and vaccine development, covering tuberculosis, dengue, and malaria.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Queensland positioned itself as a strategic partner for Indian companies in life sciences and biotechnology collaboration at BioAsia 2026. Nucleus Network participated as part of Queensland delegations, outlining areas of convergence in clinical research, vaccines, and therapeutics for tropical diseases.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global full-service CRO with established early-phase clinical pharmacology units. Competes with Nucleus Network for biotech and pharma Phase I contracts, particularly cross-region programs.

TypeBroad incumbent
Description

Global biopharmaceutical solutions organization with early-phase clinical services. Competes with Nucleus Network for Phase I biotech contracts and broader clinical development mandates.

TypeBroad incumbent
Description

Global CRO offering Phase I–IV clinical research services including early-phase units. Competes with Nucleus Network for Phase I biotech programs and large pharma outsourcing relationships.

TypeBroad incumbent
Description

Mid-sized global CRO with growing early-phase franchise and a biotech-focused commercial model. Comparable to Nucleus Network on Phase I work for emerging biotech sponsors.

TypeBroad incumbent
Description

Largest global CRO with Phase I–IV capabilities and broad biotech/pharma sponsor relationships. Overlaps with Nucleus Network on early-phase work but operates at vastly larger scale across the full clinical development lifecycle.

TypeBroad incumbent
Description

China-headquartered global CRO/CDMO with early-phase and preclinical capabilities. Competes with Nucleus Network on APAC biotech Phase I programs and on global biotech outsourcing mandates.

TypeDirect peer
Description

APAC-headquartered CRO with strong early-phase and late-phase operations, particularly in Australia and Asia. Directly comparable to Nucleus Network on regional Phase I capabilities and APAC biotech sponsors.

TypeDirect peer
Description

Global CRO with a leading early-phase / Phase I clinical services business. Highly comparable to Nucleus Network on core Phase I offering, sponsor base (biotech and large pharma), and early-phase scientific capabilities.

TypeDirect peer
Description

Australia-based early-phase clinical trial specialist operating out of Perth. Directly competes with Nucleus Network on Australian Phase I studies for biotech and pharma sponsors.

TypeDirect peer
Description

APAC-focused full-service CRO with strong early-phase presence across Australia and Asia. Competes head-to-head with Nucleus Network for regional biotech Phase I studies and shares similar sponsor overlap.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nucleus Network

Contract Research Organization (CRO) / Early-Phase Clinical Trial Servicesnucleusnetwork.com.au

Nucleus Network is an Australian CRO specializing in early-phase clinical trials for pharmaceutical and biotechnology companies. The company leverages Australia's fast-track Clinical Trial Notification Scheme and has expanded into the UK via the Hammersmith Medicines Research acquisition.

What Nucleus Network does

Nucleus Network is an Australian Contract Research Organization (CRO) founded in 2004 and headquartered in Melbourne, specializing in the conduct of early-phase clinical trials. The company serves pharmaceutical and biotechnology companies as its primary customer segment, with secondary engagement of academic and institutional research organizations. Its core offering centers on Phase I and early-phase clinical research execution, with particular domain expertise in vaccines, therapeutics, and tropical disease research including tuberculosis, dengue, and malaria. Nucleus Network operates within Australia's Clinical Trial Notification Scheme, which enables 4-8 week regulatory approval timelines, providing a structural speed advantage for sponsor drug development programs.

The company generates revenue through professional services fees for clinical trial execution on a per-study basis, with pricing negotiated quote-by-quote rather than published. As a wholly-owned portfolio company of Blackstone, Nucleus Network has pursued growth through M&A, including the 2019 acquisition of Prism Clinical Research and the August 2025 acquisition of UK-based Hammersmith Medicines Research Ltd, which extended operations beyond Australia into the United Kingdom. The company engages in event-driven go-to-market activity, notably through participation in industry conferences such as BioAsia 2026 in Hyderabad, where it positioned itself alongside the Queensland Government delegation as a strategic partner for India-Australia biotech collaboration. As of early 2026, Blackstone is evaluating a potential sale of Nucleus Network as part of its portfolio diversification strategy.

Nucleus Network firmographics

Firmographics
Name
Nucleus Network
Legal name
Nucleus Network
Website
https://nucleusnetwork.com.au
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Nucleus Network is an Australian CRO specializing in early-phase clinical trials for pharmaceutical and biotechnology companies. The company leverages Australia's fast-track Clinical Trial Notification Scheme and has expanded into the UK via the Hammersmith Medicines Research acquisition.
Ownership category
akta.pro rank

Nucleus Network industry classification

Industry
Product category
Contract Research Organization (CRO) / Early-Phase Clinical Trial Services
NAICS
Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)

Keywords

  • Early phase clinical trials
  • Contract research organization
  • Phase I trials
  • Vaccine clinical research
  • Tropical disease trials

Where Nucleus Network is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Markets served

Nucleus Network business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Research Services: Nucleus Network operates as a Contract Research Organization (CRO), providing clinical trial services to pharmaceutical and biotechnology companies. Revenue is generated through service fees for conducting clinical research trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Nucleus Network product offering

Product offering

Core offering

Nucleus Network operates as a Contract Research Organization (CRO) conducting Phase I and early-phase clinical trials for pharmaceutical and biotechnology companies. Services are delivered from Australia-based facilities with access to the Clinical Trial Notification Scheme, enabling 4-8 week trial approval timelines. The company specializes in vaccine and therapeutics clinical research, including tropical disease studies for tuberculosis, dengue, and malaria.

Product overview

Nucleus Network is a Contract Research Organization (CRO) specializing in early-phase clinical trials. Based in Australia, the company conducts Phase I and early-phase clinical research for pharmaceutical and biotechnology companies. The company is noted for fast clinical trial approval pathways and expertise in tropical health research, vaccines, and therapeutics for diseases such as tuberculosis, dengue, and malaria. Nucleus Network serves as a strategic partner for biotech collaboration between Australia and international markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early-Phase Clinical Trial Services Contract Research Organization (CRO) services delivering Phase I and early-phase clinical trials for pharmaceutical and biotechnology sponsors, leveraging Australia's Clinical Trial Notification Scheme for accelerated 4-8 week approvals.
  • Vaccines and Therapeutics Clinical Research Clinical research services focused on vaccine and therapeutics development programs for pharmaceutical and biotechnology sponsors.
  • Tropical Disease Clinical Research Specialized clinical research services for tropical disease drug and vaccine development, covering tuberculosis, dengue, and malaria.

Companies that use Nucleus Network

Customer profile

Segments2 records

Ideal customer profiles2 records

Nucleus Network technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Nucleus Network partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Queensland Government and Industry DelegationcoreStrategic or Co-development Partner · 1 February 2026Queensland positioned itself as a strategic partner for Indian companies in life sciences and biotechnology collaboration at BioAsia 2026. Nucleus Network participated as part of Queensland delegations, outlining areas of convergence in clinical research, vaccines, and therapeutics for tropical diseases.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Nucleus Network competitors and assessment

Company assessment

Broad incumbents

  • Parexel International: Global full-service CRO with established early-phase clinical pharmacology units. Competes with Nucleus Network for biotech and pharma Phase I contracts, particularly cross-region programs.
  • Syneos Health: Global biopharmaceutical solutions organization with early-phase clinical services. Competes with Nucleus Network for Phase I biotech contracts and broader clinical development mandates.
  • ICON plc: Global CRO offering Phase I–IV clinical research services including early-phase units. Competes with Nucleus Network for Phase I biotech programs and large pharma outsourcing relationships.
  • Medpace: Mid-sized global CRO with growing early-phase franchise and a biotech-focused commercial model. Comparable to Nucleus Network on Phase I work for emerging biotech sponsors.
  • IQVIA: Largest global CRO with Phase I–IV capabilities and broad biotech/pharma sponsor relationships. Overlaps with Nucleus Network on early-phase work but operates at vastly larger scale across the full clinical development lifecycle.
  • Wuxi AppTec: China-headquartered global CRO/CDMO with early-phase and preclinical capabilities. Competes with Nucleus Network on APAC biotech Phase I programs and on global biotech outsourcing mandates.

Direct peers

  • George Clinical: APAC-headquartered CRO with strong early-phase and late-phase operations, particularly in Australia and Asia. Directly comparable to Nucleus Network on regional Phase I capabilities and APAC biotech sponsors.
  • Charles River Laboratories: Global CRO with a leading early-phase / Phase I clinical services business. Highly comparable to Nucleus Network on core Phase I offering, sponsor base (biotech and large pharma), and early-phase scientific capabilities.
  • Linear Clinical Research: Australia-based early-phase clinical trial specialist operating out of Perth. Directly competes with Nucleus Network on Australian Phase I studies for biotech and pharma sponsors.
  • Novotech: APAC-focused full-service CRO with strong early-phase presence across Australia and Asia. Competes head-to-head with Nucleus Network for regional biotech Phase I studies and shares similar sponsor overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Nucleus Network social profiles

Digital presence

Nucleus Network financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nucleus Network leadership team

Management profile

Number of profiles

Profiles2 records

Nucleus Network funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nucleus Network M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nucleus Network

What does Nucleus Network do?

Nucleus Network operates as a Contract Research Organization (CRO) conducting Phase I and early-phase clinical trials for pharmaceutical and biotechnology companies. Services are delivered from Australia-based facilities with access to the Clinical Trial Notification Scheme, enabling 4-8 week trial approval timelines. The company specializes in vaccine and therapeutics clinical research, including tropical disease studies for tuberculosis, dengue, and malaria.

Is Nucleus Network a public or private company?

Nucleus Network is a private company. It is classified as private equity controlled and is currently operating.

When was Nucleus Network founded?

Nucleus Network was founded in 2004. It employs 501 to 1,000 people.

Where is Nucleus Network based?

Nucleus Network is headquartered in Melbourne, Australia, in the Oceania region.

How does Nucleus Network make money?

One revenue line is on record: clinical Research Services.

Who are Nucleus Network's main competitors?

Broad incumbents on record are Parexel International, Syneos Health, ICON plc, Medpace, IQVIA and Wuxi AppTec. Direct peers are George Clinical, Charles River Laboratories, Linear Clinical Research and Novotech.

Does Nucleus Network have an API?

No public API is recorded for Nucleus Network.

What industry is Nucleus Network in?

Nucleus Network's product category is Contract Research Organization (CRO) / Early-Phase Clinical Trial Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmaceutical TechnologyAustralia’s largest early-phase clinical trial network expands to Sydney - Pharmaceutical TechnologyNucleus Network opened a new Phase I clinical trial facility in Sydney at the North Shore Health Hub in September 2026. The unit has 41 Phase I beds, expandable to 70, and supports complex early-phase studies. The expansion adds to Nucleus Network's Australian footprint, which includes Melbourne and Brisbane.Simply Wall StBlackstone (BX) Could Be 10% Below Fair Value Following Nucleus Network Sale TalksBlackstone is seeking to sell its Australian clinical trials operator Nucleus Network, with interest from EQT and Bain Capital. The stock's DCF model values it at $113.84, above the current $128.51 price, suggesting overvaluation. The article presents conflicting views on whether the stock is undervalued.Simply Wall StHow Blackstone’s (BX) Private Credit Withdrawal Limits and Portfolio Sales May Shape Investor PerceptionBlackstone capped withdrawals from its US$77.20 billion private credit fund at 5% of shares for a second quarter amid elevated redemptions, while selling Nucleus Network and backing Waymo's $3 billion debt. The company projects $22.5 billion revenue and $9.8 billion earnings by 2029, requiring 16.1% annual revenue growth.The HinduQueensland positions itself as a strategic partner in India-Australia biotech collaboration at BioAsia 2026Queensland positioned itself as a strategic partner for Indian companies and institutions in life sciences and biotechnology collaboration at BioAsia 2026 in Hyderabad, building on the Australia-India Economic Cooperation and Trade Agreement. Key advantages highlighted include Australia's fast clinical trial approval pathways of four to eight weeks under the Clinical Trial Notification Scheme, with Queensland delegations emphasizing strengths in early-phase clinical trials, tropical health research, and advanced healthcare technologies. Representatives from Nucleus Network, Clueo Clinicals, and Australian research institutions outlined areas of convergence in clinical research, vaccines, and therapeutics for diseases such as tuberculosis, dengue, and malaria.NucleusnetworkNucleus Network Acquires Hammersmith Medicines ResearchNucleus Network acquired Hammersmith Medicines Research, a UK early-phase clinical trial organization, on August 4, 2025. The deal creates the only early-phase provider with dedicated facilities in Australia, the US, and the UK, aiming to accelerate clinical development across three continents.PR NewswirePulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute MigrainePulmatrix announced successful completion of a Phase 1 trial evaluating PUR3100, an orally inhaled dihydroergotamine formulation for acute migraine, conducted at Nucleus Network in Melbourne, Australia with 26 healthy subjects. The trial demonstrated that PUR3100 was safe and well-tolerated with fewer gastrointestinal side effects compared to intravenous DHE, achieving peak systemic exposure within the targeted therapeutic range at just five minutes across all tested doses. The company plans to request an FDA meeting this month and initiate dose selection for a Phase 2 proof-of-concept study.Welcome to the Adobe BlogNucleus Network streamlines clinical trial management with Adobe Acrobat SignNucleus Network, a clinical research organization, adopted Adobe Acrobat Sign to streamline clinical trial paperwork and meet FDA 21 CFR Part 11 compliance. The tool enables electronic signatures with phone authentication and signature manifestations, digitizing documents for its project management team. The company runs about 50 trials simultaneously, and the solution aims to reduce costs and improve speed.GlobeNewswireNFL LEGEND BRETT FAVRE AND ODYSSEY HEALTH, INC. INVOLVED WITH HUMAN TRIALS OF FIRST DRUG TREATMENT FOR CONCUSSIONOdyssey Health announced continued enrollment in its Phase 1 human trial of PRV-002, a nasal powder for concussion treatment, with Brett Favre serving as sports advisory board member. The trial is conducted by Nucleus Network in Melbourne, Australia, and the company aims to identify the most tolerated dose for subsequent efficacy studies.